trending Market Intelligence /marketintelligence/en/news-insights/trending/D4fFwiI4pVPiwPsJolUxJg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Immunomedics raises $272M from stock offering

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021


Immunomedics raises $272M from stock offering

Immunomedics Inc. closed a public offering of common shares, raising about $272 million in net proceeds.

The Morris Plains, N.J.-based company sold 16,428,572 shares for $17.50 each, including an extra 2,142,857 shares the offering's underwriters bought as part of their overallotment option.

Net proceeds will primarily be used to develop and commercialize the company's treatment for metastatic triple-negative breast cancer sacituzumab govitecan, which is under the U.S. Food and Drug Administration's review, Immunomedics said in a Dec. 9 press release.

Goldman Sachs & Co. LLC, BofA Securities, Cowen and Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering.